Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas by Salvador Coloma, Carmen et al.
OR I G I N A L R E S E A R C H
Identification Of Actionable Genetic Targets In
Primary Cardiac Sarcomas











Xavier García Del Muro3
Jaime Font de Mora 2
1Department of Medical Oncology,
Hospital Universitari i Politècnic La Fe,
Valencia, Spain; 2Laboratory of Cellular
and Molecular Biology, Clinical and
Translational Research in Cancer,
Instituto de Investigación Sanitaria La Fe,
Valencia, Spain; 3Department of Medical
Oncology, Institut Català Oncologia,
IDIBELL, L'Hospitalet de Llobregat,
Barcelona, Spain; 4Department of
Pathology, Hospital Universitari de
Bellvitge, Barcelona, Spain; 5Department
of Pathology, Hospital Universitari i
Politècnic La Fe, Valencia, Spain;
6Department of Cardiac Surgery,
Hospital Universitari i Politècnic La Fe,
Valencia, Spain
*These authors contributed equally to
this work
Background: Primary cardiac tumors are extremely rare; most are myxomas with a benign
prognosis. However, primary sarcomas are highly aggressive and treatment options are
limited. Radical surgery is often not feasible and conventional therapies provide only modest
results. Due to the rare nature of primary cardiac tumors, there are no proper randomized
studies to guide treatment. Their complexity requires alternative approaches in order to
improve treatment efficacy.
Methods: We isolated DNA from 5 primary cardiac sarcomas; the quality of DNA from 3 of
them was sufficient to perform high-resolution single nucleotide polymorphism (SNP) array
analysis.
Results: In the present study, molecular karyotyping revealed numerous segmental chromo-
somal alterations and amplifications affecting actionable genes that may be involved in
disease initiation and/or progression. These include chromosomal break flanking AKT2 in
undifferentiated pleomorphic rhabdomyosarcoma, chromosomal break in promoter of TERT,
and gain of CDK4 and amplification of MDM2 in inflammatory myofibroblastic tumor. We
detected segmental break flanking MOS in high-grade myxofibrosarcoma. In addition, the
high number of chromosomal aberrations in high-grade myxofibrosarcoma may cause multi-
ple tumor-specific epitopes, supporting the study of immunotherapy treatment in this type of
aggressive tumor.
Conclusion: Our results provide a genetic rationale that supports an alternative, persona-
lized therapeutic management of primary cardiac sarcomas.
Keywords: primary cardiac sarcomas, molecular karyotype, actionable genes
Introduction
Primary cardiac tumors are extremely rare, with a global incidence of 0.0017–
0.019% per year.1 Heart metastases are over 20 times more frequent than primary
cardiac tumors.2 Benign primary cardiac tumors are the most prevalent (around
75%) of which are myxomas.3 Malignant primary neoplasms are uncommon and
sarcomas represent 20% of all cases.4,5 The most common subtypes are angiosar-
coma (37%), followed by MFH (24%), leiomyosarcoma (9%), rhabdomyosarcoma
(7%), unclassified (7%) and others (16%).6 These malignant tumors rapidly invade
all layers of the heart and metastasize, with over 80% of patients presenting
metastasis at diagnosis.7 Prevalence between males and females has not been
reported and the mean age of presentation is 40 years.8
The symptoms depend on the location and the extent of the tumor. In some
patients, detection of tumors is incidental, although in most cases, due to the
aggressive nature of the tumors, there are symptoms which are usually non-specific.
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Symptoms include those derived from an obstruction to
blood flow and impairment of valvular function, embo-
lism, local myocardial invasion causing arrhythmia or
pericardial effusion, or systemic symptoms of dyspnea
(the most common symptom 60%), fever, malaise and
weight loss.6,9
In most cases, a transthoracic echocardiography is the
method of initial evaluation. A transesophageal echocar-
diography can provide valuable information, especially in
difficult locations where the transthoracic route may not be
sensitive enough. Cardiac magnetic resonance imaging
(MRI), and computed tomography (CT) scan provide com-
plementary information. In selected cases, a coronary
angiography is specifically required to assess the location
of the tumor’s nutrient vessels. The CT scan and MRI of
the chest and abdomen are complementary and can show
the extracardiac extent of the tumor and presence of
metastases.
We present a series of five primary cardiac sarcomas.
We performed molecular karyotyping of three samples
using high-resolution SNP arrays and found genetic altera-
tions that may provide alternative treatment options to
improve the outcome of cardiac sarcomas.
Materials And Methods
Human Subject Research
This study was carried out according to the code of ethics
of the World Medical Association (Declaration of
Helsinki). Informed consent was obtained, and the study
was approved by the author’s institutional review board.
Immunohistochemistry
Immunohistochemistry was performed as described earlier
in a two-step staining method by a Techmate 500 immu-
nostainer (DAKO).10 Antibodies used from DAKO were
as follows: cytokeratin proteins (clone AE1-AE3), vimen-
tin (V9), desmin (D33), smooth muscle actin (1A4), mus-
cle-specific actin (HHF35), S-100 (#GA504), melanosome
(HMB45), CD31 (JC0A), CD34 (QBEnd), CD68 (KP1),
CD3 (#GA503), CD20 (L26), CD45LCA (2B11+PD7/26),
estrogen receptor (EP1), progesterone receptor (PgR636),
factor VIII (#GA527), Ki67 (MIB-1), kappa chain
(#GA506), gamma chain (#GA512), calretinin (DAK-
Calret 1), WT1 (6F-H2), epithelial membrane antigen
(E29), Myogenin (clone F5D), smooth muscle actin
(1A4) and E-cadherin (NCH38).
Fluorescence In Situ Hybridization
Paraffin-embedded tissue sections were hybridized with
FISH Break-apart probe (Vysis LSI SS18 Dual Color
Break Apart Probe-Abbott Molecular Inc) following the
manufacturer’s protocol.
DNA Extraction And Molecular
Karyotyping
DNA from tumor-selected sections of paraffin-embedded
tissues was isolated with QIAamp DNA Investigator Kit
(QIAGEN). Integrity of the DNA was assessed by Qubit
and further analyzed by molecular karyotyping with SNP
arrays (Oncoscan, Affymetrix). SNP array results were
analyzed with Chromosome Analysis Suite software
(Affymetrix, ChAS; version 3.1). The annotation version
used by the ChAS software is based on the February 2009
human reference sequence GRCh37 (hg19). SNP array
data quality was assessed with the internal array quality
control parameter “Median of the Absolute Values of all
Pairwise Differences” (MAPD). SNP array data were
plotted and interpreted as described previously.11
Results
Case Report 1
A 50-year-old woman attended the Emergency Department
with palpitations and worsening dyspnea. Her previous med-
ical history consisted of a ductal breast carcinoma treated 4
years before with chemotherapy followed by surgery and
radiotherapy. The electrocardiogram showed a supraventri-
cular tachycardia. CTscan revealed amass in the right atrium.
A transthoracic echocardiogram (TTE) showed an immobile,
heterogeneous, intracavitary mass (41×34mm) in the right
atrium.The initial presumptive diagnosiswas an intracavitary
thrombus (Figure 1). Anticoagulants and beta-blockers were
given. However, the patient’s condition quickly worsened
with persistent hypotension and tachycardia. She underwent
emergency cardiac surgery and thrombectomy and incom-
plete resection of the mass was performed.
Histopathological examination revealed an undifferen-
tiated pleomorphic sarcoma positive for smooth muscle
actin (SMA) and vimentin expression, weak and focal stain-
ing for cytokeratin AE1-AE3, 90% Ki67 (Figure 2) and
positivemargins. Immunostaining was negative for epithelial
membrane antigen, desmin, S-100, melanosome, CD31,
CD34, factor VIII, estrogen and progesterone receptors,
and CD45. Mesenchymal cells of medium and large size
were very atypical and arranged in a vaguely fascicular
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pattern with marked pleomorphism. There was also a mas-
sive thrombosis on the right atrium with an extension to the
inferior vena cava. The patient received palliative
CHEMOTHERAPY with non-pegylated liposomal doxoru-
bicin-ifosfamide, resulting in stable disease after 3 cycles.
Due to high-grade hematological toxicity, treatment was
changed to weekly paclitaxel and a partial response was
obtained. Unfortunately, disease symptoms reappeared after
7 months of treatment, and her clinical condition quickly
worsened. She died 19 months after the initial diagnosis.
Molecular karyotype with SNPs array showed several
segmental chromosomal aberrations (SCA, indicative of
Figure 1 (A) CT scan of the chest and (B) CT scan of the abdomen reveal a hypodense and heterogeneous mass in the atrium.
Figure 2 (A) Hematoxylin eosin staining at 10× magnification and (B) at 20× magnification showing atypical mesenchymal cell proliferation of fascicular pattern with
numerous mitotic figures and necrosis areas. (C) Positive immunostaining for vimentin, (D) smooth muscle actin (SMA), (E) cytokeratins AE1/AE3 and F 90% Ki67
proliferation index.
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chromosomal break points) that led to 50% to 100%
mosaic gains in 2p21p22.2, 4p14pter, 6p21.1pter (flanked
by the osteoblast differentiation transcription factor
RUNX2), 13q31.1qter, 17p11.1pter, 19q13.11qter (flanked
by AKT2) and 22q11.1q13.1 (Figure 3). A mosaic loss in
10q11.23qter (50%) was also detected, but no whole
numerical chromosomal alterations (NCA) were observed
with this technique.
Case Report 2
A 72 years-old woman with unremarkable previous medical
history was admitted to the hospital due to high fever and
chest pain. CT scan revealed a cardiac mass in the right
atrium with a myxoid compound, invading the inferior vena
cava and suprahepatic veins. Study revealed a heart MRI
with a multi-lobulated 60mm mass and associated thrombus
(Figure 4A and B). Anticoagulant treatment was started and
she underwent cardiac surgery with an incomplete resection.
The pathological examination revealed a heterogeneous
mesenchymal proliferation of large polygonal cells (40%
Ki67 expression level) embedded in a collagenous stroma
with extensive necrotic areas (Figure 5). Immunostaining for
muscle-specific actin, desmin and myogenin were positive
(data not shown). The final diagnosis was a high-grade
pleomorphic rhabdomyosarcoma of the heart.
CT scan after surgery showed thrombosis of the pul-
monary artery associated with pulmonary infarction and
bilateral pleural effusion (Figure 4C). The patient pre-
sented congestive heart failure, and despite medical inter-
ventions, her clinical condition quickly deteriorated and
she died 3 months after the initial diagnosis.
Case Report 3
A 66-year-old woman with no medical history entered the
hospital with orthopnea and progressive dyspnea. The
physical examination displayed signs of severe left heart
failure and CT scan revealed an immobile, homogeneous,
intracavitary mass in the septum of the left atrium (4×3cm)
which extended into the right inferior pulmonary vein.
She underwent surgery with radical excision of the
mass in February 2015 (Figure 6). The pathologist diag-
nosed an inflammatory myofibroblastic neoplasm. Stromal
cells were positive for SMA, calponin, focal CD68, focal
XIIa factor. Infiltrating inflammatory cells were polyclonal
kappa and gamma chains positive (Figure 7). She recov-
ered after surgery but had local relapse 37 months after the
initial diagnosis, followed by a second surgical resection
Figure 3 Molecular karyotype in circos plot of the undifferentiated pleomorphic
rhabdomyosarcoma (case report 1). Allele peaks (inner plots) and weighted
Log2ratio (middle plots) information were obtained from Affymetrix software
ChAS and further used to generate circos plot.
Figure 4 (A) Cardiac Magnetic Resonance Imaging of the pericardial tumor with a maximum diameter of 69.48 mm. (B)Large mass arising from the pericardium adjacent to
the right atrium, which extends superiorly towards the left pulmonary artery. (C). Lesion relapsed arising from the pericardium in the right atrium which is invading the right
ventricle. It is associated with extending thrombosis towards the suprahepatic veins and inferior cava vein. Bilateral pleural effusion.
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of the tumor. One year later she was diagnosed with two
brain lesions and finally died of brain metastasis 56
months after initial diagnosis. SNP array analysis of the
primary tumor revealed alterations in TERT, CDK4 and
Figure 5 (A) Hypercellular areas with focal necrosis (H-E 10×). (B) The cells showed large, irregular nuclei and prominent nucleoli, with a wide, eosinophilic cytoplasm. (C)
Cells with rhabdoid features and cytoplasmatic cross striations (H-E 40×). (D) Diffuse proliferation with a storiform growth pattern, embedded in a collagenous/myxoid
stroma (H-E 10×).
Figure 6 (A) CT scan of the abdomen and (B) CT scan of the chest reveal a large tumor in the left atrium extending to the lower pulmonary vein.
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MDM2, among others (Figure 8). FISH analysis of the
relapsed tumor confirmed MDM2 amplification (data not
shown).
Case Report 4
A 51-year-old man with no previous medical history
arrived at the Emergency Department with shortness of
breath, chest pain, and an episode of conscience loss.
Physical examination revealed severe hypotension and
tachycardia. The TTE revealed a large pericardial effusion
consistent with a cardiac tamponade. A pericardiocentesis
was performed and the patient was admitted for further
analysis. A CT scan identified a 3×65 mm irregular mass
in the pericardium of the right atrium (Figure 9). He
underwent cardiac surgery and pathologic examination of
biopsy revealed a heterogeneous cell proliferation with a
biphasic pattern, composed of epithelial cells forming
solid nests and glandular structures separated by spindle
cells forming intersecting fascicles (Figure 10A). Mitotic
rate was estimated as 4 mitotic cells per field using the
20X objective and resection margins were positive.
Immunohistochemistry was positive for vimentin, BCL2
and epithelial markers (AE1/AE3 and CK7), epithelial
membrane antigen, SMA, calretinin, and WT1
(Figure 8B and C and not shown). Fluorescent in-situ
Figure 7 (A) Hematoxylin-eosin staining at 10× magnification and (B) at 20× magnification showing mixed inflammatory infiltrate, occasional plasma cells and mesenchymal
spindle cells without atypia or mitotic figures. (C) Cells CD68+. (D) T-lymphocytes CD3+. (E) B-lymphocytes CD20+. (F) Smooth muscle actin.
Figure 8 Molecular karyotype in circos plot of the inflammatory myofibroblastic
tumor (case report 3). Allele peaks (inner plots) and weighted Log2ratio (middle
plots) information were obtained from Affymetrix software ChAS and further
used to generate circos plot. Paraffin-embedded tissue with a 50–60% tumor cell
content was used for molecular karyotype analysis, revealing a 25% mosaic
numerical chromosomal gain in whole chromosome 8 and numerous SCAs
including 25–50% mosaic losses in 1q21.1qter, 2p25.3pter, 4q12.2qter,
9p13.2pter, 16q12.2q24.3; two sub-telomeric amplifications (4+1 allele copies)
in 5p15.33 containing TERT promoter in the flanking breakpoint and in
5p15.2p15.31, gains (3+1 allele copies) in 2q11.1qter, 11q14.1, 12q13.2q13.3
and in 12q13.3q14.1 containing CDK4, and amplification (9 copies) in
12q14.3q21.1 region containing MDM2.
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Figure 9 (A) Diagnostic computed tomography scan. Pericardial effusion with heterogenic areas suggesting recent bleeding. Pericardial tumor mass depending on the right
atrium wall. (B) Computed tomography scan showing progression of the pericardial mass that measures 154×93.5 mm and presents mass effect on the right cavities.
Composed of vascular structures and necroticoquistic areas.
Figure 10 (A) Biphasic synovial sarcoma showing epithelial structures surrounded by spindle cells. (B) The epithelioid cells showed immunohistochemical expression of
cytokeratin 7, (C) whereas the spindle cell component displayed a predominant vimentin expression. (D) FISH break-apart probe result was consistent with a translocation,
yielded one yellow fusion, one red and one green pattern.
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hybridization (FISH) showed SYT translocation (18q11.2)
in 90% of tumor cell nuclei, further supporting the diag-
nosis of high-grade biphasic synovial sarcoma of the peri-
cardium (Figure 10D).
Four cycles of adjuvant chemotherapy based on ifosfa-
mide and epirubicin were administrated. A control CT
scan in April 2015 suggested relapse. The patient was
administered palliative chemotherapy with DTIC plus
gemcitabine but the disease was continued to progress
after 4 cycles. Therefore, a new line of chemotherapy
was started with trabectedin but the patient was admitted
to the hospital for congestive heart failure. He deteriorated
rapidly and died due to congestive heart failure and tumor
progression.
Case Report 5
A 27-year-old man with no previous medical history arrived
at the Emergency Department with shortness of breath,
orthopnea, tachypnea and cyanosis. He had a rhythmic
tachycardia and 80% oxygen saturation. Chest radiography
showed an alveolar pattern. Transthoracic echocardiogram
revealed a mass on the left atrium protruding into the
ventricle. Another extra-cardiac mass was detected on the
right ventricle wall, and based on these findings, emergency
surgery was performed (Figure 11). Pathologic examination
revealed medium-sized spindle-shaped cells distributed in a
myxoid stroma with focal necrosis in 20% of the sample.
Cells of variable sizes, some of them enormous, displayed
well-defined eosinophilic cytoplasm with pleomorphic
nuclei. Immunohistochemical analysis revealed a very
focal, cytoplasmic expression of desmin and myogenin
and no expression of SMA, calponin, caldesmon or
MyoD1, consistent with a high-grade myxofibrosarcoma
(Figure 12). SYT translocation was also analyzed by FISH
and was negative. Expression of the proliferation marker
Ki67 was 35% and the resection edges were affected (not
shown).
CT scan was consistent with incomplete tumor resec-
tion. After three chemotherapy cycles with epirubicin and
ifosfamide, a cardiac MRI revealed the disappearance of
the pericardial collection and intracardiac masses loss.
Treatment was completed for a total of six cycles with
an excellent tolerance. He currently maintains a complete
response with no progression.
SNPs array analysis showed a high number of NCAs as
well as SCAs, suggesting multiple rearrangements and a
complex karyotype (Figure 13). Notably, chromothripsis
was also detected in chromosomes 12q and 18q
(Figure 13). Similarly to case report 3, CDK4 and MDM2
were also amplified (7 copies each).
Discussion
Many types of sarcomas have been reported in the
heart,5,7,8,12,13 although due to their rarity, most have
been isolated case reports. Cardiac MRI provides useful
information for characterizing cardiac masses and their
anatomical localization. Thus, masses in the left atrium
are more commonly benign, whereas masses in the right
atrium and pericardium are more often malignant.14
However, three of the five cases we report originally
affected the left atrium: primary pleomorphic
Figure 11 Surgical exposure of the heart confirmed an extra-cardiac mass on the
left atrium protruding into the ventricle.
Figure 12 Hematoxylin and eosin staining in case report 5 revealed a myxoid
variant of a high-grade undifferentiated pleomorphic sarcoma with moderate inflam-
matory infiltration.
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rhabdomyosarcoma, inflammatory myofibroblastic
tumor, and myxofibrosarcoma. Although benign myxo-
mas are the most common tumors occurring in the left
atrium, malignant tumors can simulate myxomas and
should be considered in the differential diagnosis.15
Undifferentiated pleomorphic tumours are usually
poorly differentiated, with atypical spindle cells, high mito-
tic activity, necrosis, and nuclear polymorphism.16,17 The
prognosis of these aggressive tumours is generally poor.
Although radical surgery offers an important means for
alleviating symptoms, local recurrence and metastasis
occur usually within 1 year. Chemotherapy and radiation
therapy have limited benefit in most published cases.18 A
recent study of an undifferentiated cardiac intimal sarcoma
using next-generation sequencing reported an activating
mutation in PDGFRB, suggesting a novel therapeutic target
for this rare disease.19 Our molecular karyotype analysis
identified numerous gains and losses with two well-defined
segmental breaks flanked by AKT2 and RUNX2 genes,
suggesting that deregulation of these two genes may also
be involved in disease initiation and/or progression.
Primary pleomorphic rhabdomyosarcomas in the heart
are extremely rare and the risk of hemodynamic complica-
tions and cardiac failure determine the generally poor
prognosis of these tumors. In our case, the tumor rapidly
progressed after an initial surgical resection and the patient
developed rapidly progressive congestive heart failure. To
our knowledge, only one other case of this pathology was
been reported,20 which emphasizes the rarity of this con-
dition and the relevance of reporting our own experience
to improve the management of this disease.
The inflammatory myofibroblastic tumor is a very rare
intracardiac neoplasia. It mainly occurs in children and
young adults, and although the most common location is
the lung, it has also been described in other sites (pelvis,
head and neck, abdomen, liver, etc.) and exceptionally in
the heart.21 The specificity of ALK may help in differential
diagnosis and can be efficiently targeted with ALK
inhibitors.22 Molecular karyotype analysis in our patient
revealed a 50% mosaic NCA (2 to 3 chromosomes) for
whole chromosome 2, where ALK is located. Taking into
account that tumor cell content in the sample analyzed was
around 60%, our results suggest that almost all tumor cells
had an extra copy of chromosome 2. However, this tech-
nique is not adequate for the detection of ALK transloca-
tions if no copy number alterations are involved.
Noteworthy, we identified two subtelomeric amplicons in
5p, one of them with the segmental break right at TERT
promoter, suggesting a role for telomere maintenance in
this disease. In addition, we detected a small segment 12q
gain (4 copies) containing CDK4 gene and a nearby 9
copies-amplification containing MDM2 gene. Our results
further support previous findings in an oral inflammatory
myofibroblastic tumor23 and in two primary cardiac
tumors24,25 and provide a rationale for applying precision
medicine approaches to these types of tumors with TP53
therapy (PRIMA-1 or MDM2 inhibitors) and CDK4 inhi-
bitors such as palbociclib. The neoplastic nature of inflam-
matory myofibroblastic tumors and the possible relation
with inflammatory events are still debated: some excep-
tional spontaneous or steroid-induced regression has been
described,26 but surgical resection remains the treatment of
choice. Despite the infrequent relapse of inflammatory
myofibroblastic tumors (25–35%), those arising within
the heart are very rare and scant cases with incomplete
resection may result in rapid local relapse.27,28 The case
Figure 13 Molecular karyotype in circos plot of our reported high-grade myx-
ofibrosarcoma (case report 5). Allele peaks (inner plots) and weighted Log2ratio
(middle plots) information were obtained from Affymetrix software ChAS and
further used to generate circos plot. NCA gains and losses were detected at
variable mosaicisms in chromosomes −3, +9, +13, +14 (2+2 allele copies), +15,
+16 (2+2), +17, +20 (2+2), +21 and −22. SCAs were detected in +1p21.1pter,
−1p13.1p21.1, +1q21.1qter (2+2), +2q11.2pter, −2q11.2q14.1, +2q14.1qter,
+4p12pter, +5p12pter (4–5 copies), +6q15pter (2+2), +6q15qter, +7q11.21pter
(3+1), +7q11.21qter, −8q12.1pter, +8q12.1qter (2+2), −10p12.2pter,
−10q11.21q21.3, +10q24.1qter, −11p11.2pter, +12p11.21pter, −12q21.2q23.1,
+12q23.1q24.32, −12q24.32qter, −18q12.1pter, +18q21.32qter, +19q13.31pter
(2+2), +19q13.31qter, +Xp11.21pter. An amplification in 8q (average of 7 copies)
containing the Pleomorphic adenoma gene 1 (PLEG1) was flanked by MOS proto-
oncogene promoter. Chromosomes 4, 12p, 12q23.3-12qter and 18q21.32qter
displayed loss of heterozygosity (LOH).
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we report with brain metastasis showed the long-term poor
outcome, suggesting that ensuring complete resection is
not enough and supporting the use of alternative strategies
in addition to surgical resection plus conventional therapy.
Primary synovial sarcoma arising from the pericardium is
an extremely rare disease, as most of them arise from the
extremities, displaying a preference for juxta-articular loca-
tion. The mainstay of the diagnosis is the detection of the
reciprocal translocation t(X; 18) (p11.2; q11.2) and
SS18-SYT fusion gene by FISH, which is present in more
than 80% of the cases.29 Although very little is known about
the oncogenic pathways triggered by the chimeric protein
SS18X-SYT, it is thought to play a role in the transcriptional
deregulation of targeted genes.30 Cytogenetic analysis pro-
vides an added value in the confirmation of the diagnosis,
being especially useful when they arise from atypical sites.
The management of synovial sarcoma is challenging and
requires a personalized treatment strategy. A broad surgical
resection is the cornerstone of therapy when feasible. The
external beam radiation therapy (EBR) is used when the
margins of resection are positive. Despite the initial radical
management, the prognosis is poor with 12-month disease-
free survival.31 Currently, new molecular-targeted therapies
are under investigation, such as trastuzumab in those who
express HER2.32
Myxofibrosarcoma is one of the most aggressive var-
iants of soft tissue neoplasms. Although it usually involves
the left atrium, in our case, the ventricles were affected.
Consistent with being high-grade and aggressiveness, our
reported myxofibrosarcoma displayed highly complex
chromosomal rearrangements with NCAs, LOHs, SCA
gains and losses, amplifications and chromothripsis. All
these alterations reflect high chromosomal instability and
suggest the role of genomic maintenance genes in this
disease. In addition, these multiple rearrangements may
result in multiple tumor-specific epitopes, and hence,
immunotherapy would be an interesting treatment option
to explore in these cases.
In conclusion, cardiac sarcomas proliferate rapidly and
cause death in most cases with 6–12 months of median
survival.13 The complexity of heart sarcomas requires
personalized management of each case and alternative
strategies in order to improve short and long-term out-
come. They should be treated in specialized oncology
centers, in order to obtain an accurate diagnosis and
improve treatment efficacy. Observations from our study
support the implementation of genetic analysis of primary
cardiac sarcomas to identify actionable targets for a
precision medicine strategy that may improve the prog-
nosis of these rare oncologic diseases.
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